New painkiller may cut opioid use after breast reduction
NCT ID NCT05891613
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tested two different painkillers in 32 women having breast reduction surgery. Each woman received a long-acting painkiller (liposomal bupivacaine) on one breast and a standard painkiller (bupivacaine hydrochloride) on the other. The goal was to see which one provided better pain relief and reduced the need for opioid painkillers in the first three days after surgery.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Liposomal bupivacaine (Exparel) and bupivacaine hydrochloride
- What this could lead to
- If it works, this could point toward a better way to manage pain after breast reduction, possibly reducing the need for opioids.
- What could go wrong
- This is a small, single-blind, non-randomized trial with only 32 participants, so results may not apply to everyone. The benefit may be small or not clinically meaningful.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
32 people
The number who actually took part.
- Started
-
Jan 2024
- Finished
-
Oct 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 70 years
- Sex
-
Female participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria \- Adult female patients (18-70 years old) with symptomatic macromastia scheduled for breast reduction using a Wise pattern incision design. Exclusion Criteria * Inability to provide informed consent * Medical or surgical history precluding breast reduction * History of significant chronic pain requiring daily use of opioid or nonopioid analgesics * Pregnancy * Concomitant non-breast surgical procedure * Previous chest wall irradiation * Previous breast implant, breast reduction or breast lift surgery * Known allergy to bupivacaine or liposomal bupivacaine * Liver or kidney dysfunction * Use of antiplatelet or anticoagulation therapy.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast reduction are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic Minnesota
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.